Global Korean Company Celltrion, Inc. to start a partnership with Kobe Biomedical Innovation Cluster to promote Korean Startups’ Business Development in Japan and Around the World

We are pleased to announce that Celltrion, Inc., a biotechnology company from the Republic of Korea, which has demonstrated a new business paradigm through the development of the world's first antibody biosimilar, has opened its first Japan office in Kobe Biomedical Innovation Cluster (KBIC) collaborating in the activities to support Korean startups to develop their business in KBIC. Celltrion will actively promote Korean startup by multiple activities such as participating in the startup support program “Kansai Life Science Accelerator Program (KLSAP)” as a sponsor company, facilitating business matching and networking for Korean startups with KBIC companies and by hosting event for Korean and Japanese startups in KBIC.

xCARE Inc. has raised 130 million yen through a third-party allocation of new shares on January 15, 2024

xCARE announced that it has raised 130 million yen through a third-party allocation of new shares on January 15, 2024. With this funding, we will strengthen product development based on our expert database, marketing and branding of our platform " xCARE", and overseas expansion (North America and Europe).

Bayer Yakuhin held an event "Startup x Pharma Connect by Bayer in Kobe" co-hosted by Kobe City and FBRI to exchange opinions on activating the drug discovery innovation ecosystem with the drug discovery startups mainly based in Kansai

On December 19th, Bayer Yakuhin held an event "Startup x Pharma Connect by Bayer in Kobe", which was co-hosted by Kobe City and FBRI (Foundation for Biomedical Research and Innovation at Kobe), to exchange opinions on activating the drug discovery innovation ecosystem with the drug discovery startups mainly based in Kansai.

RNA Analysis of Circulating Leukocytes in Patients with Alzheimer’s Disease: FBRI’s research team’s findings published in Journal of Alzheimer's Disease on January 22, 2024

MiCAN Technologies Established a Development Office in Europe at Biolabs Heidelberg for the Development of an Alternative Thermogenic Test Product (MylcMAT) Using Human Immortalized Monocyte Cells (aMylc)

MiCAN Technologies Inc. (hereinafter referred to as “MiCAN”), a member company of Kobe Biomedical Innovation Cluster (KBIC) is developing a MAT (Monocyte Activation Test) product (MylcMAT) using human immortalized monocyte cells (aMylc) with its proprietary blood cell production technology. In Europe, the rabbit thermogenicity test has been decided to discontinue by the end of 2025 due to its high burden on animals. Therefore, it is desired to develop and provide an alternative testing method that does not use animal resources.